Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

A combination of belzutifan, pembrolizumab, and lenvatinib showed encouraging results as first-line treatment for advanced RCC in an early phase trial. Phase 3 trial data are pending. Among first-line ...

This case report details an incident of pembrolizumab-induced myasthenia gravis in an elderly male patient being treated for urothelial cell bladder cancer. Researchers are calling for further ...

The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer. The FDA has approved pembrolizumab (Keytruda; Merck ...

Ramez N. Eskander, MD, discusses the optimal use of lenvatinib/pembrolizumab in clinical practice for patients with ...

New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for ...